Figure 1.

Unadjusted and adjusted cumulative incidence of major adverse cardiovascular event among users and non-users of GLP-1 receptor agonist. GLP-1 RAs, GLP-1 receptor agonists; MACE, major adverse cardiovascular event. Cumulative incidence curve is adjusted for: age, sex, smoking, body mass index, estimated glomerular filtration rate category, comorbidities (heart failure, cancer, hypertension, percutaneous coronary intervention, coronary artery bypass grafting, stroke, peripheral vascular disease, atrial fibrillation, Killip, ST-segment elevation myocardial infarction), and cardiovascular medications (aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, P2Y12 inhibitors).